Health and Economic After-effects in Leicester Tuberculosis Cohort (HEAL-TB)
Quantifying the Short to Long-term Physical, Psychological, and Socioeconomic Consequences of Pulmonary and Extra-pulmonary Tuberculosis in Patients in Leicester: a Longitudinal Cohort Study.
HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.
Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.
The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Detailní popis
HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.
The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.
The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Jake Bodycot
- Telefonní číslo: +447551792221
- E-mail: jb1071@leicester.ac.uk
Studijní místa
-
-
-
Leicester, Spojené království, LE1 5WW
- University Hospitals of Leicester NHS Trust
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.
Popis
Inclusion Criteria:
- Aged 16 years or above.
- Any sex/gender.
- Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
- Willing and able to provide informed consent to participate in the study.
Exclusion Criteria:
- Expected to move out of the area or unable to attend follow-up visits.
- Prisoners or people under custodial care.
- Currently involved in research or recently involved in other research.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: COHORT
- Časové perspektivy: PROSPECTIVE
Počet skupin / kohort
Kohorty a intervence
Skupina / kohortaSkupina / kohorta |
|---|
|
Pulmonary Tuberculosis
Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
|
Extrapulmonary Tuberculosis
Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Health-related quality of life measured by EQ-5D-5L
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Depressive symptoms measured by PHQ-9
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Anxiety symptoms measured by GAD-7
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Lung function measured by spirometry
Časové okno: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Physical activity measured by wrist-worn activity monitor
Časové okno: Study entry and applicable follow-up assessments through 6 months after treatment completion
|
Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels. |
Study entry and applicable follow-up assessments through 6 months after treatment completion
|
|
Work productivity and activity impairment measured by WPAI
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Functional exercise capacity measured by Incremental Shuttle Walk Test
Časové okno: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres. |
Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face
|
|
Respiratory-specific quality of life measured by St George's Respiratory Questionnaire
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
|
Participant-reported recovery from tuberculosis
Časové okno: Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit. |
Study entry and applicable follow-up assessments through 12 months after treatment completion
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Spolupracovníci
Spolupracovníci
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Manish Pareek, University of Leicester
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- 1107
- 223512/Z/21/Z (Jiné číslo grantu/financování: Wellcome Trust)
- 365242 (Jiný identifikátor: IRAS)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .